PURPOSE: To characterize the degree of contrast enhancement within the ablation zone immediately after radiofrequency (RF) ablation of renal tumors. MATERIALS AND METHODS: Patients with renal tumors treated with percutaneous RF ablation at one institution between January 2004 and October 2007 were retrospectively reviewed. For each tumor, computed tomography (CT) density measurements were made at four phases (noncontrast, arterial phase, parenchymal phase, and excretory phase) in each of four CT examinations (before ablation, day 0, 1 month, and 6 months). RESULTS: A total of 36 renal tumors in 34 patients were treated with CT-guided RF ablation in 35 sessions. Before RF ablation, all tumors exhibited enhancement after intravenous administration of contrast material. The peak density was reached during the parenchymal phase, with a partial washout of contrast agent in the excretory phase. On CT images acquired immediately after RF ablation (day 0), 28 of the 36 ablated tumors (78%) exhibited clinically significant homogeneous enhancement (ie, density change >10 HU) within the ablation zone. However, contrast-enhanced CT studies performed at 1 and 6 months revealed no clinically significant enhancements in any of the 36 treated tumors (mean density changes of 4 HU at 1 month and 3 HU at 6 months). CONCLUSIONS: Contrast-enhanced CT studies revealed a mild, temporary homogenous contrast enhancement of the ablation zone immediately after RF ablation of renal tumors, which should not be mistaken for a residual, unablated tumor. This enhancement in the ablation zone eventually disappears in follow-up contrast-enhanced CT studies.
PURPOSE: To characterize the degree of contrast enhancement within the ablation zone immediately after radiofrequency (RF) ablation of renal tumors. MATERIALS AND METHODS:Patients with renal tumors treated with percutaneous RF ablation at one institution between January 2004 and October 2007 were retrospectively reviewed. For each tumor, computed tomography (CT) density measurements were made at four phases (noncontrast, arterial phase, parenchymal phase, and excretory phase) in each of four CT examinations (before ablation, day 0, 1 month, and 6 months). RESULTS: A total of 36 renal tumors in 34 patients were treated with CT-guided RF ablation in 35 sessions. Before RF ablation, all tumors exhibited enhancement after intravenous administration of contrast material. The peak density was reached during the parenchymal phase, with a partial washout of contrast agent in the excretory phase. On CT images acquired immediately after RF ablation (day 0), 28 of the 36 ablated tumors (78%) exhibited clinically significant homogeneous enhancement (ie, density change >10 HU) within the ablation zone. However, contrast-enhanced CT studies performed at 1 and 6 months revealed no clinically significant enhancements in any of the 36 treated tumors (mean density changes of 4 HU at 1 month and 3 HU at 6 months). CONCLUSIONS: Contrast-enhanced CT studies revealed a mild, temporary homogenous contrast enhancement of the ablation zone immediately after RF ablation of renal tumors, which should not be mistaken for a residual, unablated tumor. This enhancement in the ablation zone eventually disappears in follow-up contrast-enhanced CT studies.
Authors: Tze Min Wah; Steven Sourbron; Daniel Jonathan Wilson; Derek Magee; Walter Martin Gregory; Peter John Selby; David L Buckley Journal: Diagnostics (Basel) Date: 2018-01-08